Full Press Release Details
By Electronic Delivery to: mguerin@onconova.us
Chief Financial Officer
Onconova Therapeutics, Inc.
Re: Onconova Therapeutics, Inc. (the Company )
On May 7, 2018, Staff notified the Company that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by the Listing Rules of The Nasdaq Stock Market. Since then, Staff has determined that for the last 10 consecutive business days, from September 26, 2018 to October 9, 2018, the closing bid price of the Company s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed.
If you have any questions, please contact me at +1 301 978 8368.
Kathryn A. Warcholak
Nasdaq Listing Qualifications